Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Institutions of which they are part Head of group Biomedical Research in Cancer Stem Cells Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Matilde Lleonart Pajarin LinkedIn Twitter Orcid Institutions of which they are part Head of group Biomedical Research in Cancer Stem Cells Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Projects Estudi de la resistència a fàrmacs en carcinoma de cèl·lules escamoses de cap i coll (HNSCC) IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 90983.33 Reference: IFI18/00046 Duration: 01/01/2019 - 20/09/2023 Biomedical Research in Cancer Stem Cells IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2017SGR01121 Duration: 01/01/2017 - 31/12/2020 GC16173720CARR Definición de mecanismos clave de la multiresistencia de tumores de cabeza y cuello a los tratamientos quimio- y radioterapéuticos. Identificación de nuevos antitumorales individualizados. IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea, Juan Lorente Guerrero, Josep Castellví Vives, Vicente Peg Camara, Almudena Sanchez Garcia Funding agency: Asociación Española Contra el Cáncer Funding: 380000 Reference: AECC/GCE/2016/LLEONART Duration: 01/10/2016 - 30/09/2022 Nuevas terapias aplicables a cánceres mamarios de naturaleza agresiva y metastática en base a aniquilar la población de células madre de cáncer. IP: Matilde Lleonart Pajarin Collaborators: Margarita Alberola Ferranti, Carmela Iglesias i Felip, Josep Castellví Vives Funding agency: Instituto de Salud Carlos III Funding: 195415 Reference: PI15/01262 Duration: 01/01/2016 - 30/11/2020 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 … Next page › Last page »
